Awareness, Care & Treatment In Obesity Management - An Observation in Asia Pacific (ACTION-APAC)

ACTION APAC is a cross-sectional, observational, descriptive, and exploratory survey-based study without collection of laboratory data. The study is not related to any specific treatment options or pharmaceutical product. Collection of data will be performed via quantitative online survey by a third-party vendor through existing databases/panels in APAC region.

The goal of this study is to provide insights to drive awareness around the needs of People Living with Obesity (PLwO) and Health Care Professionals (HCPs) involved in obesity treatment and management.

Study Overview

• Status: Completed
• Conditions: Obesity
• Intervention / Treatment: Other: No treatment given

• Study Type: Observational
• Enrollment (Actual): 12404

Contacts and Locations

Study Locations

• Bangladesh
  • Dhaka, Bangladesh
    • Novo Nordisk Investigational Site
• India
  • Bangalore, India
    • Novo Nordisk Investigational Site
• Indonesia
  • Jakarta, Indonesia
    • Novo Nordisk Investigational Site
• Malaysia
  • Kuala Lumpur, Malaysia
    • Novo Nordisk Investigational Site
• Pakistan
  • Karachi, Pakistan
    • Novo Nordisk Investigational Site
• Philippines
  • Manila, Philippines
    • Novo Nordisk Investigational Site
• Singapore
  • Singapore, Singapore
    • Novo Nordisk Investigational Site
• Thailand
  • Bangkok, Thailand
    • Novo Nordisk Investigational Site
• Vietnam
  • Ho Chi Minh, Vietnam
    • Novo Nordisk Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

The respondent population will include people living with obesity (PLwO) and health care professionals (HCPs) involved in obesity treatment and management.

Description

Inclusion criteria:

People Living with Obesity

1. Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
2. Male or female, aged above or equal to 18 years at the time of signing informed consent
3. Lives in one of the target countries
4. Current BMI of at least 25 kg/m^2 for all countries (except Singapore which has current BMI 27 kg/m^2) based on self-reported height and weight

Health Care Professionals

1. Informed consent before any study related activities (study-related activities are any procedure related to recording/collection of data according to protocol)
2. Male or female, aged greater than or equal to 18 years at the time of signing informed consent.
3. Physician
4. Primary Care Providers (PCPs) whose specialty is Family practice, General practice, Internal Medicine
5. Non-PCP Specialties whose specialty is Endocrinologist, Cardiologist, Gastroenterologist, Obstetrics/Gynaecologist, Bariatrics/Obesity Medicine, Nutrition Specialist (physician) Orthopaedist, Aesthetics Medicine
6. Specialty is not surgeon (including bariatric or plastic surgeon)
7. Practices in the target countries
8. In clinical practice for at least 2 years
9. Spends at least 50% time in direct patient care
10. Has seen at least 100 patients in past month
11. Has seen at least 10 patients in past month who have obesity defined as: a patient with a BMI greater than or equal to 25 kg/m^2 for all countries (except Singapore which has current greater than or equal to BMI 27 kg/m^2) with or without comorbidities.

Exclusion criteria:

People Living with obesity

1. Previous participation in this study. Participation is defined as having given online consent in this study
2. Currently pregnant
3. Participates in intense fitness or body building programs
4. Has had significant, unintentional weight loss (due to major injury, illness, etc) in the past 6 months
5. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

Health Care Providers

1. Previous participation in this study. Participation is defined as having given informed consent in this study.
2. Unwillingness, inability, or language barriers precluding adequate understanding or cooperation

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Cross-Sectional

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
People / Person Living with Obesity (PLwO); From online, general population consumer panels	Other: No treatment given; No treatment given
Health Care Professionals (HCPs); HCPs treating people who have obesity	Other: No treatment given; No treatment given

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Weight loss motivators for improving health of PLwO	Multi-select from defined list	At the time of survey response (Day 1)
Weight loss barriers for improving health of PLwO	Multi-select from defined list	At the time of survey response (Day 1)
Weight loss management for improving health of PLwO	Multi-select from defined list	At the time of survey response (Day 1)
Weight loss responsibility for improving health of PLwO	Multi-select from defined list	At the time of survey response (Day 1)
Proportion of PLwO who made serious weight loss effort	Number of weight loss efforts; percentage of patients	At the time of survey response (Day 1)
Response to weight loss discussions	Single select from defined list	At the time of survey response (Day 1)
Attitudes towards obesity and weight management and Interactions of PLwOs with HCPs	5-point Likert scales	At the time of survey response (Day 1)

Collaborators and Investigators

• Sponsor: Novo Nordisk A/S

Study record dates

Study Major Dates

• Study Start (Actual): April 26, 2022
• Primary Completion (Actual): May 23, 2022
• Study Completion (Actual): May 23, 2022

Study Registration Dates

• First Submitted: February 11, 2022
• First Submitted That Met QC Criteria: February 11, 2022
• First Posted (Actual): February 22, 2022

Study Record Updates

• Last Update Posted (Actual): June 14, 2022
• Last Update Submitted That Met QC Criteria: June 13, 2022
• Last Verified: June 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Overnutrition; Nutrition Disorders; Overweight; Body Weight; Obesity
• Other Study ID Numbers: DAS-006; U1111-1266-5484 (Other Identifier: World Health Organization (WHO))

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Yes
• IPD Plan Description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No